Characterizing the antimicrobial activity of cisplatin against Gram-positive clinical strains: bridging existing gaps

Authors

  • Sulaiman Bani Abdel-Rahman Department of Microbiology and Pathology, Faculty of Medicine, Mutah University, P.O. Box 7, Mutah, Al-Karak, 61710, Jordan
  • Hala Altarawneh Department of Microbiology and Pathology, Faculty of Medicine, Mutah University, P.O. Box 7, Mutah, Al-Karak, 61710, Jordan
  • Mohammed Abu Lubad Department of Microbiology and Pathology, Faculty of Medicine, Mutah University, P.O. Box 7, Mutah, Al-Karak, 61710, Jordan
  • Hamed Alzoubi Department of Pathology and Microbiology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan
  • Khulud A. Alhazmi Department of Microbiology and Parasitology, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
  • Ohood S Alharbi Department of Microbiology and Parasitology, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
  • Malaz Gazzaz Pharmaceutical Practices Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia
  • Mohanned Talal Alharbi Department of Basic Medical Sciences, College of Medicine, University of Jeddah, Jeddah, Saudi Arabia
  • Rawan Altalhi Department of Biological Sciences, College of Science, University of Jeddah, Jeddah 23445, Saudi Arabia
  • Waiel S Halabi Department of Optometry, Faculty of Applied Medical Sciences, University of Jeddah, Jeddah 23218, Saudi Arabia
  • Asim T Sharif Department of Medical Education, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia https://orcid.org/0009-0003-7882-4085
  • Bayan Redwan Department of Medical Education, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
  • Mazen A Ismail Department of Medical Education, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
  • Ahmad M Sait Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia https://orcid.org/0000-0002-1698-5444
  • Khalil Alkuwaity Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia https://orcid.org/0009-0005-5689-7683
  • Wafaa Alhazmi Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
  • Sultan A Alfawaz Department of Clinical Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia https://orcid.org/0009-0008-0343-0301
  • Hussam Daghistani Regenerative Medicine Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia https://orcid.org/0000-0001-8491-8350
  • Bandar Hasan Saleh Department of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia https://orcid.org/0000-0002-3205-2986
  • Mona Abdulrahman Alqarni Department of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
  • Abdulaziz Alsaedi Department of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia https://orcid.org/0009-0001-4435-6274
  • Nabeel Hussain Alhussainy Department of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia https://orcid.org/0009-0004-4315-5982
  • Hatoon A Niyazi Department of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
  • Hanouf A Niyazi Department of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
  • Dalya M Attallah Department of Clinical Microbiology Laboratory, King Abdulaziz University Hospital, Jeddah 21589, Saudi Arabia https://orcid.org/0009-0006-0082-1177
  • Karem Ibrahem Department of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

DOI:

https://doi.org/10.3855/jidc.21822

Keywords:

Cisplatin, Multidrug-resistant bacteria, MIC, MRSA, VRE

Abstract

Introduction: Multidrug resistant (MDR) bacteria are one of the most important current threats to public health. Therefore, serious concerns were raised about the effectiveness of traditional antibiotics. Cisplatin, a chemotherapeutic agent that is used mainly in cancer treatment, has recently attracted attention and popularity for its potential antibacterial properties. Our study aim is to evaluate the antibacterial properties of cisplatin against several common MDR and non-MDR Gram-positive strains, including Methicillin-Resistant Staphylococcus aureus (MRSA), Methicillin-Susceptible Staphylococcus aureus (MSSA), Coagulase-Negative Staphylococcus (CoNS), and Vancomycin-Resistant Enterococcus (VRE).

Methodology: Cisplatin's Minimum Inhibitory Concentration (MIC) was calculated through standard microdilution methods.

Results: Our findings indicated that cisplatin had a minimum inhibitory concentration (MIC) of 256 µg/mL across all tested bacterial strains, reflecting its limited antibacterial efficacy in its currently available formulation. However, although the MIC values were high, this study explored cisplatin’s activity against these bacterial strains which uncovers a potential gap about cisplatin clinical effectiveness and indicates that further enhancement is required.

Conclusions: These results confirm that cisplatin antibacterial activity has not been extensively explored against these resistant strains. Cisplatin alone shows limited efficacy based on the relatively high MIC values observed. However, combination therapy with other antibiotics may improve its therapeutic potential. Additionally, novel delivery systems—nanoparticle formulations, for instance—could enhance antibacterial activity while reducing toxicity. Future investigations should evaluate these approaches in more detail.

Downloads

Published

2026-06-30

How to Cite

1.
Bani Abdel-Rahman S, Altarawneh H, Abu Lubad M, Alzoubi H, Alhazmi KA, Alharbi OS, Gazzaz M, Alharbi MT, Altalhi R, Halabi WS, Sharif AT, Redwan B, Ismail MA, Sait AM, Alkuwaity K, Alhazmi W, Alfawaz SA, Daghistani H, Saleh BH, Alqarni MA, Alsaedi A, Alhussainy NH, Niyazi HA, Niyazi HA, Attallah DM, Ibrahem K (2026) Characterizing the antimicrobial activity of cisplatin against Gram-positive clinical strains: bridging existing gaps. J Infect Dev Ctries 20:802–809. doi: 10.3855/jidc.21822

Issue

Vol. 20 No. 06: June 2026

Section

Original Articles

License

Copyright (c) 2026 Sulaiman Bani Abdel-Rahman, Hala Altarawneh, Mohammed Abu Lubad, Hamed Alzoubi, Khulud Alhazmi, Ohood Alharbi, Malaz Gazzaz, Mohanned Alharbi, Rawan Altalhi, Waiel Halabi, Asim Sharif, Bayan Redwan, Mazen Ismail, Ahmad Sait, Khalil Alkuwaity, Wafaa Alhazmi, Sultan Alfawaz, Hussam Daghistani, Bandar Saleh, Mona Alqarni, Abdulaziz Alsaedi, Nabeel Alhussainy, Hatoon Niyazi, Hanouf Niyazi, Dalya Attallah, karem Ibrahem

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Crossref
Scopus
Google Scholar
Europe PMC